Dr. Michael Serzan emphasizes the importance of clinical trial participation for patients with kidney cancer.
Dr. Michael Serzan
Advertisement
Serzan is a medical oncologist in the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, as well as an instructor of medicine at Harvard Medical School, located in Boston.
Articles by Dr. Michael Serzan
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Dr. Michael Serzan provides expert takeaways on treatment updates for patients with early-stage kidney cancer following the 2025 ASCO Meeting.
Advertisement
Latest Updated Articles
A New Therapeutic Approach May Make Waves in Kidney Cancer TreatmentPublished: June 12th 2025 | Updated:
Zanzalintinib Triplet Combo Under Investigation in Kidney Cancer SubgroupsPublished: June 17th 2025 | Updated:
Advertisement
Advertisement
